These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24040873)

  • 21. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
    Sumida Y; Yoneda M; Tokushige K; Kawanaka M; Fujii H; Yoneda M; Imajo K; Takahashi H; Eguchi Y; Ono M; Nozaki Y; Hyogo H; Koseki M; Yoshida Y; Kawaguchi T; Kamada Y; Okanoue T; Nakajima A; Jsg-Nafld JSGON
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.
    Kovalic AJ; Satapathy SK; Chalasani N
    Hepatol Int; 2018 Mar; 12(2):97-106. PubMed ID: 29600430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
    Li CL; Zhao LJ; Zhou XL; Wu HX; Zhao JJ
    J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):333-336. PubMed ID: 26072069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
    Tang W; Xu Q; Hong T; Tong G; Feng W; Shen S; Bi Y; Zhu D
    Diabetes Metab Res Rev; 2016 Feb; 32(2):200-16. PubMed ID: 26381272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
    Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
    Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
    Mazzotti A; Caletti MT; Marchignoli F; Forlani G; Marchesini G
    Dig Liver Dis; 2017 Mar; 49(3):235-240. PubMed ID: 28089623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.
    Ng CH; Lin SY; Chin YH; Lee MH; Syn N; Goh XL; Koh JH; Quek J; Hao Tan DJ; Mok SF; Tan E; Dan YY; Chew N; Khoo CM; Siddiqui MS; Muthiah M
    Endocr Pract; 2022 Feb; 28(2):223-230. PubMed ID: 34606980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus.
    Fujimori N; Tanaka N; Kimura T; Sano K; Horiuchi A; Kato N; Takahashi Y; Kuribayashi N; Sugiura A; Yamazaki T; Joshita S; Umemura T; Matsumoto A; Tanaka E
    Clin J Gastroenterol; 2020 Feb; 13(1):83-89. PubMed ID: 31292843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
    Wang XC; Gusdon AM; Liu H; Qu S
    World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
    Sumida Y; Seko Y; Yoneda M;
    Hepatol Res; 2017 Mar; 47(4):266-280. PubMed ID: 28019064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
    Iogna Prat L; Tsochatzis EA
    Hormones (Athens); 2018 Jun; 17(2):219-229. PubMed ID: 29858843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver-targeting drugs and their effect on blood glucose and hepatic lipids.
    Gastaldelli A; Stefan N; Häring HU
    Diabetologia; 2021 Jul; 64(7):1461-1479. PubMed ID: 33877366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease.
    Lamos EM; Kristan M; Siamashvili M; Davis SN
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):837-852. PubMed ID: 33882758
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-diabetic drugs and NASH: from current options to promising perspectives.
    Smati S; Canivet CM; Boursier J; Cariou B
    Expert Opin Investig Drugs; 2021 Aug; 30(8):813-825. PubMed ID: 34214406
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.